Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans

NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
April 28, 2026 07:30 ET | Source: Cytokinetics, Incorporated

Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress

SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026...
April 28, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

BRANFORD, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2...
April 27, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis présente sa plateforme d’édition épigénétique pour éteindre des gènes sans modifier l’ADN, lors du congrès annuel de l’ASGCT

NEW YORK, 27 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome...
April 27, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...
April 27, 2026 08:10 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Oncolytics Biotech announced Type C meeting with the FDA aligning on the design of clinical study to support approval of pelareorep in patients with SCAC.
April 23, 2026 12:14 ET | Source: PridCor Therapeutics, LLC

PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses

PridCor secures global antiviral portfolio with Phase 2b and Phase 3 assets to advance treatments for Long COVID and chronic illness.
April 23, 2026 12:00 ET | Source: World Street Intelligence

Five Under-the-Radar Stocks With Catalysts Already in Motion — Across AI Defense, Space, Longevity, Gold, and Post-Quantum Security

Issued on behalf of VisionWave Holdings, Inc., Starfighters Space, Inc., Avaí Bio, Inc., Lake Victoria Gold Ltd., and QSE – Quantum Secure Encryption Corp. Five small-cap companies operating in very...
April 23, 2026 09:20 ET | Source: InnoCare Pharma

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

InnoCare remained profitable in the first quarter of 2026, with net profit increasing by 607.7% YoY to RMB 102.4 million.
April 23, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+...